Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD – a major contribution to a growing body of evidence supporting this treatment. At Numinus, we’re excited to add to this knowledge through our collaboration with MAPS PBC on our compassionate access trial of MDMA for PTSD, starting in summer 2021. Through this trial, we will be able to deliver MDMA-assisted psychotherapy for PTSD to individuals with treatment-resistant PTSD who are unable to access MDMA-assisted therapy through a Phase 3 trial. Key milestones have since been announced, including the finalization of treatment protocols, training of trial therapists and appointment of lead investigators.
“Our compassionate access trial seeks to provide additional safety data to Health Canada that we expect will add to this impressive Phase 3 data to support eventual approval of MDMA-assisted psychotherapy for Canadians with PTSD,” said Dr. Devon Christie, Medical and Therapeutics Services Director of Numinus and Principal Investigator of the compassionate access trial by Numinus and MAPS. “The results highlight the importance of continued efforts such as those by Numinus to bring these treatments to the mainstream.”
Dr. Christie, explains further in this short video.